Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
Title:
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
Author:
Slamon, D.J. Neven, P. Chia, S. Jerusalem, G. De Laurentiis, M. Im, S. Petrakova, K. Valeria Bianchi, G. MartÃn, M. Nusch, A. Sonke, G.S. De la Cruz-Merino, L. Beck, J.T. Ji, Y. Wang, C. Deore, U. Chakravartty, A. Zarate, J.P. Taran, T. Fasching, P.A.